Convalescent plasma therapy for patients with hematologic cancers and COVID-19
Dr. Jeremy Warner
Prior studies have established hematologic cancers as a risk factor associated with particularly poor outcomes from COVID-19. A retrospective cohort study by the COVID-19 and Cancer Consortium found a potential survival benefit in the administration of convalescent plasma to patients with hematologic cancers and COVID-19.
